×
To share and enhance best practice management of CML, experts and interested clinicians can discuss difficult or interesting CML cases here. Physicians submit a brief history of the patient and the case for discussion (no more than 200 words) by posting it in this forum ("New Discussion" button below). Please include the country of origin.
Each clinical case will be forwarded to the expert clinical panel for a brief independent response. Consideration should be given to patient confidentiality. Details that are not critical to the case can be changed to preserve anonymity. Please consider including your email with the case. This will not be posted on the website, but is useful should further details be requested by the moderator.
As a full clinical history is necessary for accurate comment, cases and comments on the Forum are ONLY ACCEPTED FROM PHYSICIANS. If individual patients have a specific question we encourage them to contact their healthcare provider. General questions can be emailed to info@cml-foundation.org.
DISCLAIMER: The iCMLf does not recommend or endorse any specific tests, physicians, products, procedures, or opinions, and disclaims any representation, warranty, or guaranty as to the same. Reliance on any information provided in this Forum is solely at your own risk.
Out of a total of about 300 plus patients of CML on treatment at our center, 2 are HIV positive and are on HART.
Both are on Imatinib 400 mg/day and tolerating the well.
No experience with the 2nd Gen TKIs.
The problem for the patient is taking too many drugs per day leading to compliance issues.
Also, anemia, because of the ART or Imatinib, is an issue in these patients.
No other issues with toxicities or responses.
I have 2 HIV+CML and 1 HES FIP1 positive patients on Imatinib. Imatinib is well tolerated and all of these are in complete cytogenetic response. There are also some published evidence about a synergistic effect of HART and IM.
This website uses cookies to manage authentication, navigation, and other functions. By using our website, you agree that we can place these types of cookies on your device.View our Privacy Policy